Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00212342 |
Recruitment Status
:
Completed
First Posted
: September 21, 2005
Last Update Posted
: September 8, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dysmenorrhea | Drug: Norethisterone,Ethinylestradiol Drug: Sugar pill | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Phase 3,Placebo Controlled,Randomized,Double-Blinded,NSAID-Add-on,Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis. |
Study Start Date : | December 2004 |
Actual Primary Completion Date : | January 2006 |
Actual Study Completion Date : | March 2006 |

Arm | Intervention/treatment |
---|---|
Experimental: Norethisterone,Ethinylestradiol | Drug: Norethisterone,Ethinylestradiol |
Placebo Comparator: Sugar pill | Drug: Sugar pill |
- patient response to treatment for dysmenorrhea associated with endometriosis,as evaluated by VRS
- changes in the VAS of dysmenorrhea.
- changes in the VRS of non-menstrual pain.
- changes in the VAS of non-menstrual pain.
- changes in the clinical evaluation of pelvic induration.
- changes in the size of ovarian endometrioma.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- dysmenorrhea associated with endometriosis
Exclusion Criteria:
- severe hepatopathy
- pregnant woman

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00212342
Study Director: | Naoki Terakawa, M.D.,Ph.D. | Tottori University,Tottori,Japan |
ClinicalTrials.gov Identifier: | NCT00212342 History of Changes |
Other Study ID Numbers: |
IKH-01-4 |
First Posted: | September 21, 2005 Key Record Dates |
Last Update Posted: | September 8, 2010 |
Last Verified: | September 2010 |
Additional relevant MeSH terms:
Dysmenorrhea Menstruation Disturbances Pathologic Processes Pelvic Pain Pain Neurologic Manifestations Signs and Symptoms Contraceptive Agents Norethindrone Norethindrone acetate |
Contraceptives, Oral Ethinyl Estradiol Contraceptives, Oral, Combined Reproductive Control Agents Physiological Effects of Drugs Contraceptive Agents, Female Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Contraceptives, Oral, Synthetic |